ABBV-706
- Generic Name
- ABBV-706
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau /ID# 257294, Barcelona, Spain
🇪🇸Hospital Universitario Ramon y Cajal /ID# 257291, Madrid, Spain
🇪🇸Hospital Universitario Fundacion Jimenez Diaz /ID# 257295, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath